O simulador de gestão de tabernas Tavern Keeper abre novas profundidades, permitindo a construção de cellares, logística de funcionários e um novo cenário de campanha nas montanhas de Domhain.

Cellares will support automated manufacturing of GF-CART01 as GenomeFrontier tests the cell therapy in patients with B-cell malignancies.

After layoffs, cell therapy manufacturer Cellares has inked a new deal. The CEO says, "The strategy hasn't changed, the fundamentals also have not changed."

Manufacturing roundup: Novartis licenses Alteogen's Hybrozyme tech; Cellares cuts 68 more NJ jobs; Novonesis, Aspen, Fortrea and Northway expand.

Cellares plans to eliminate 68 jobs at its Bridgewater site as the biotech restructures after losing a pharma partnership.

This Week’s CGT News: Bristol Myers Ends Cellares Manufacturing Agreement  themedicinemaker.com

August has seen a slew of executive hires, exits and layoffs across the healthcare industry. For instance, Humana, Merck and Mayo Clinic named new executives. There were also layoffs at organizations including MaineHealth, Cellares and Sharp HealthCare.

Bristol-Myers Squibb Company (NYSE:BMY) has ended its partnership with cell-therapy manufacturer Cellares after determining that Cellares' Cell Shuttle

The restructuring comes after an unnamed "large pharmaceutical customer" terminated a contract with the company, Cellares CEO Fabian Gerlinghaus posted on LinkedIn.

Cellares cuts 100 jobs after Bristol Myers ends Breyanzi manufacturing deal; startup disputes claims its Cell Shuttle tech fell short.

Bristol Myers Squibb has ended its partnership with cell therapy startup Cellares to expand the manufacturing of its ​personalized blood cancer therapy, a company spokesperson told ‌Reuters on Tuesday.

Bristol Myers exits its Cellares CAR-T manufacturing deal after the Cell Shuttle falls short, prompting a reorg at Cellares.

Fast-growing biotech manufacturer loses major customer, plans layoffs

Officials at Cellares say the Integrated Development and Manufacturing Organization (IDMO) entered multiple strategic technology partnerships to advance the Cell Q™, a fully automated quality control testing platform purpose-built to match the commercial-scale throughput for cell therapy manufacturing. Cellares is unveiling these partnerships ahead of the 10th Annual CAR-TCR Summit, where it will, for the first time, present drug product release data automatically generated on the Cell Q and case studies highlighting the automation of system verification, thawing, assay preparation, and execution of vector copy number (VCN) quantification.

Cellares secures new funding, partnerships and FDA recognition as it prepares for commercial-scale cell therapy manufacturing.